Condition: Behçet's Disease · Juvenile Psoriatic Arthritis · Sponsor: Amgen
The primary objective of this study is to evaluate the long-term safety of apremilast in subjects 2 years of age or older with oral ulcers associated with Behçets disease or 5 years of age or older with active juvenile psoriatic arthritis that have completed Study 20190530 or Study 20190529.
This description comes directly from the study's public registry record.
Amgen Call Center · 866-572-6436 · medinfo@amgen.com
Always discuss trial participation with your own doctor first.
| General Hospital of Thessaloniki Ippokrateio | Thessaloniki, Greece | Recruiting |
| Meir Medical Center | Kfar Saba, Israel | Recruiting |
| Hospital Universitari i Politecnic La Fe | Valencia, Valencia, Spain | Recruiting |
| Hospital Universitario Ramon y Cajal | Madrid, Spain | Recruiting |
| Hacettepe Universitesi Tip Fakultesi Hastanesi | Ankara, Turkey (Türkiye) | Recruiting |
| Istanbul Universitesi Cerrahpasa Tip Fakultesi | Istanbul, Turkey (Türkiye) | Recruiting |
| Umraniye Egitim ve Arastirma Hastanesi | Istanbul, Turkey (Türkiye) | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05767047